Recent Finacing
Recent Raise
CoviCept develops a small‑molecule antiviral targeting a host protein required for RNA viral replication, with a lead compound showing SARS‑CoV‑2, Zika and Dengue activity and Phase 1 human safety/bioavailability.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
See the team members at CoviCept Therapeutics.
